Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humora...
        Saved in:
      
    
          | Published in | Molecules and cells Vol. 44; no. 6; pp. 392 - 400 | 
|---|---|
| Main Authors | , | 
| Format | Journal Article | 
| Language | English | 
| Published | 
        United States
          Korean Society for Molecular and Cellular Biology
    
        01.06.2021
     한국분자세포생물학회  | 
| Subjects | |
| Online Access | Get full text | 
| ISSN | 1016-8478 0219-1032 0219-1032  | 
| DOI | 10.14348/molcells.2021.0075 | 
Cover
| Summary: | It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants, and highlight gaps in the current knowledge. | 
|---|---|
| ISSN: | 1016-8478 0219-1032 0219-1032  | 
| DOI: | 10.14348/molcells.2021.0075 |